Investigation the Relationship Between Myonectin Levels and Both Lipid Profiles and Liver Function Tests in Diabetic Nephropathy Patients

Authors

  • Zahraa. M. Ismail Department of Chemistry, College of Science, Mustansiriyah University, Baghdad, Iraq.
  • Falah S. Al-Fartusie Department of Chemistry, College of Science, Mustansiriyah University, Baghdad, Iraq.
  • Noor. T. Tahir National Diabetes Centre/ Mustansiriyah University, Baghdad, Iraq.
  • Ahmed H. Ismail Department of Chemistry, College of Science, Mustansiriyah University, Baghdad, Iraq.Department of Chemistry, College of Science, Mustansiriyah University, Baghdad, Iraq.

Myonectin, or CTRP12, is a relatively recent adipokine—a protein released by adipose tissue that has gained interest in the context of metabolic health, including its possible implications in diabetic complications. Volunteers were divided into three groups, healthy subjects as controls (group A), they don't suffer from any disease, patients with T2D without nephropathy  (group B) and T2D with nephropathy (group C), the age ranges between (35-70) years and the average duration disease of T2D (5-25) years, attending to the AL-Kindi teaching hospital, Baghdad Iraq. There was a highly significant increase P ≤ 0.01 of FBS, Insulin level, HOMA-IR, HbA1c, TC, TG, HDL and TSB among different groups (T2D with nephropathy, T2D without nephropathy, and control), a highly significant increase P ≤ 0.01 of myonectin levels among different groups. There was no significant difference present in AST U/L, and ALP U/L. A statistically significant increase in ALT U/L when compared with the control group. Conclusion: Levels of serum myonectin were significantly higher in patients with (T2D without nephropathy) as compared with ( T2D with nephropathy) and the control group.

Keywords:

Myonectin, T2D, HbA1c, Diabetic nephropathy, Lipid profile.

[1] P. Saeedi et al., ‘Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition’, Diabetes Res. Clin. Pract., vol. 157, 2019, doi: 10.1016/j.diabres.2019.107843.

[2] M. Li et al., ‘Association of ANGPTL8 and Resistin With Diabetic Nephropathy in Type 2 Diabetes Mellitus’, Front. Endocrinol. (Lausanne)., vol. 12, 2021, doi: 10.3389/fendo.2021.695750.

[3] N. Samsu, ‘Diabetic Nephropathy: Challenges in Pathogenesis, Diagnosis, and Treatment’, Biomed Res. Int., vol. 2021, 2021, doi: 10.1155/2021/1497449.

[4] G. Russo et al., ‘Atherogenic dyslipidemia and diabetic nephropathy’, J. Nephrol., vol. 33, no. 5, pp. 1001–1008, 2020, doi: 10.1007/s40620-020-00739-8.

[5] J. Donate-Correa et al., ‘Inflammatory targets in diabetic nephropathy’, J. Clin. Med., vol. 9, no. 2, 2020, doi: 10.3390/jcm9020458.

[6] G. Ferrannini, N. Rosenthal, M. K. Hansen, and E. Ferrannini, ‘Liver function markers predict cardiovascular and renal outcomes in the CANVAS Program’, Cardiovasc. Diabetol., vol. 21, no. 1, 2022, doi: 10.1186/s12933-022-01558-w.

[7] D. J. Nunez et al., ‘Factors influencing longitudinal changes of circulating liver enzyme concentrations in subjects randomized to placebo in four clinical trials’, Am. J. Physiol. - Gastrointest. Liver Physiol., vol. 316, no. 3, pp. G372–G386, 2019, doi: 10.1152/ajpgi.00051.2018.

[8] G. E. Chung et al., ‘Combined Effects of Chronic Kidney Disease and Nonalcoholic Fatty Liver Disease on the Risk of Cardiovascular Disease in Patients with Diabetes’, Biomedicines, vol. 10, no. 6, 2022, doi: 10.3390/biomedicines10061245.

[9] A. Muendlein et al., ‘the New Myokine Myonectin Is Significantly Associated With Type 2 Diabetes in Patients With Peripheral Artery Disease’, J. Am. Coll. Cardiol., vol. 77, no. 18, p. 1791, 2021, doi: 10.1016/s0735-1097(21)03147-8.

[10] M. Kawaguchi, N. Kawao, Y. Takafuji, M. Ishida, and H. Kaji, ‘Myonectin inhibits the differentiation of osteoblasts and osteoclasts in mouse cells’, Heliyon, vol. 6, no. 5, 2020, doi: 10.1016/j.heliyon.2020.e03967.

[11] K. Li et al., ‘Myonectin predicts the development of type 2 diabetes’, J. Clin. Endocrinol. Metab., vol. 103, no. 1, pp. 139–147, 2018, doi: 10.1210/jc.2017-01604.

[12] W. Chen, L. Wang, W. You, and T. Shan, ‘Myokines mediate the cross talk between skeletal muscle and other organs’, J. Cell. Physiol., vol. 236, no. 4, pp. 2393–2412, 2021, doi: 10.1002/jcp.30033.

[13] R. M. Khadim and F. S. Al-Fartusie, ‘Evaluation of Liver Function and Lipid profiles in Iraqi patients with Rheumatoid Arthritis’, in Journal of Physics: Conference Series, 2021, vol. 1853, no. 1, p. 12040.

[14] M. N. Farhan, F. S. Al-Fartusie, and S. L. Hamed, ‘Evaluation of lipid profile and liver function in acute pancreatitis patients: A case control study’, Ann. Trop. Med. Public Heal., vol. 23, no. 18, 2020, doi: 10.36295/ASRO.2020.231826.

[15] S. S. Falih, F. S. Al-Fartusie, and N. T. Tahir, ‘Association between lipid profile and other biochemical parameters with growth hormone in children and adolescents with short stature’, Int. J. Res. Pharm. Sci., vol. 11, no. 3, pp. 4295–4302, 2020, doi: 10.26452/ijrps.v11i3.2642.

[16] A. Shokoohi Nahrkhalaji, R. Ahmadi, R. Fadaei, G. Panahi, M. Razzaghi, and S. Fallah, ‘Higher serum level of CTRP15 in patients with coronary artery disease is associated with disease severity, body mass index and insulin resistance’, Arch. Physiol. Biochem., vol. 128, no. 1, pp. 276–280, 2022, doi: 10.1080/13813455.2019.1675713.

[17] D. K. Das, Z. A. Graham, and C. P. Cardozo, ‘Myokines in skeletal muscle physiology and metabolism: Recent advances and future perspectives’, Acta Physiol., vol. 228, no. 2, 2020, doi: 10.1111/apha.13367.

[18] S. JS et al., ‘Interest of albuminuria in nephrology, diabetology and as a marker of cardiovascular risk.’, Ann. Biol. Clin. (Paris)., vol. 77, no. 1, pp. 26–35, 2019, [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/30799295/.

[19] J. Zhang, ‘16TH Annual World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)’, Endocr. Pract., vol. 25, no. 1, pp. 1–43, 2019, doi: 10.4158/1934-2403-25.1.1A.

[20] J. L. Petro, M. C. Fragozo-Ramos, A. F. Milán, J. C. Aristizabal, J. A. Gallo-Villegas, and J. C. Calderón, ‘Serum Levels of Myonectin Are Lower in Adults with Metabolic Syndrome and Are Negatively Correlated with Android Fat Mass’, Int. J. Mol. Sci., vol. 24, no. 8, 2023, doi: 10.3390/ijms24086874.

[21] Q. Mi et al., ‘Circulating C1q/TNF-related protein isoform 15 is a marker for the presence of metabolic syndrome’, Diabetes. Metab. Res. Rev., vol. 35, no. 1, 2019, doi: 10.1002/dmrr.3085.

[22] Z. Qi et al., ‘Codon-optimized FAM132b gene therapy prevents dietary obesity by blockading adrenergic response and insulin action’, Int. J. Obes., vol. 46, no. 11, pp. 1970–1982, 2022, doi: 10.1038/s41366-022-01189-x.

[23] T. Uchiyama, H. Ota, C. Ohbayashi, and S. Takasawa, ‘Effects of intermittent hypoxia on cytokine expression involved in insulin resistance’, Int. J. Mol. Sci., vol. 22, no. 23, 2021, doi: 10.3390/ijms222312898.

Investigation the Relationship Between Myonectin Levels and Both Lipid Profiles and Liver Function Tests in Diabetic Nephropathy Patients. (2024). Journal Port Science Research, 7(1), 30-35. https://doi.org/10.36371/port.2024.1.5

License

Copyright (c) 2024 Journal Port Science Research

Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

How to Cite

Investigation the Relationship Between Myonectin Levels and Both Lipid Profiles and Liver Function Tests in Diabetic Nephropathy Patients. (2024). Journal Port Science Research, 7(1), 30-35. https://doi.org/10.36371/port.2024.1.5